Navigation Links
Clinical trials for shingles drug take an important step forward
Date:5/11/2009

A possible new anti-viral drug designated FV-100, which could alleviate the suffering of millions of people with herpes zoster or shingles, has entered the second stage of clinical testing in patients.

Developed and patented by scientists based at Cardiff University, a Phase II clinical trial with FV-100 has recently been initiated in America. Previous research has shown the drug to be up to 10,000 times more potent than existing treatments in early lab tests.

The drug was discovered by a team in the Welsh School of Pharmacy and a virology group at the Rega Institute in Belgium, and is being further developed in collaboration with the U.S - based biopharmaceutical company, Inhibitex Inc. If it successfully demonstrates both safety and biological activity in this and subsequent trials, the treatment has the potential to improve the lives of over 2.5 million herpes zoster patients worldwide.

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that around one in five people in the U.S., Europe and Japan will be affected by the debilitating condition during their lifetime. It is generally characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia (PHN), which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Inhibitex believes FV-100 has the potential to reduce all of these symptoms.

Cardiff University's Professor of Medical Chemistry Chris McGuigan, who led the team which discovered the anti-viral drug said:

"We believe this drug has the potential to be the most powerful inhibitor ever discovered to treat shingles.

"Each year only 25 new medicines are approved for clinical use [worldwide or by the FDA]. Although FV-100 is early in its overall development plan, the chances of it becoming an approved medicine improves the further we successfully progress through each of the clinical stages. We are incredibly excited at the prospect of FV-100 becoming commercially available in the future, and potentially being the first drug discovered in Cardiff University to make it to the marketplace."

In Phase I trials of FV-100, Inhibitex reported no serious adverse events in healthy volunteers and data supported the potential for once-a-day dosing in future trials. Inhibitex anticipates completing its first Phase II trial of FV-100 in the first half of 2010.

Russell H. Plumb, president and chief executive officer of Inhibitex, Inc said: "We have more than 20 U.S sites qualified to enroll patients, and plan to ultimately utilise a total of 50-60 sites in this trial. We believe this enthusiastic response from the clinical community reflects its recognition of the significant unmet medical needs of the increasing number of shingles patients."


'/>"/>

Contact: Professor Chris McGuigan
mcguigan@cardiff.ac.uk
44-292-087-4537
Cardiff University
Source:Eurekalert

Related biology news :

1. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
4. Cleveland Clinic leading clinical program to improve early-stage lung cancer detection
5. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
6. Study of African traditional medicine will begin world-first clinical trial
7. New clinical data shows chromium picolinate improves cognitive function
8. New clinical trial results show how personalized medicine will alter treatment of genetic disorders
9. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. NHLBI issues first US von Willebrand Disease clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic ... to mergers and acquisitions (M&A), and Kalorama Information expects ... such acquisitions have been shifting. Generally, uncertainty in reimbursement ... and the U.S. has changed the acquisitions landscape. Instead ... resulted in companies buying partners outside of their home ...
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/13/2017)... , Jan. 13, 2017 Sandata Technologies, ... for the homecare industry, including Electronic Visit Verification™ ... expert, Justin Jugs, as Senior Vice President of ... 15 years of homecare experience to Sandata, where ... strategic plans to align Sandata,s suite of solutions ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... 2017 , ... The American Medical Informatics Association (AMIA) today ... Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should be ... recommended that NIH earmark funding for researchers to produce and execute data sharing ...
(Date:1/19/2017)... Ca (PRWEB) , ... January 18, 2017 , ... ... events for tech innovators, engineers, and scientists from around the world, was today ... News. The awards program is based entirely on merit and decided upon by ...
(Date:1/19/2017)... Island, NY (PRWEB) , ... January 19, 2017 , ... ... at an exponential rate. The tremendous growth is accounted to two main factors. ... the table and the expanding network of vendors supplying FireflySci products all around the ...
(Date:1/19/2017)... ... 19, 2017 , ... DaVita Clinical Research (DCR), ... and device development, and Prism Clinical Research , a leader in providing ... Verified Clinical Trials (VCT) has been selected by both companies as an ...
Breaking Biology Technology: